Live: Will Palantir Beat Q1 Earnings Tonight After Market Close?

Health and Healthcare

AbbVie : ABBV

All AbbVie Articles

566 Articles

Chris Lange | Jul 26, 2017 at 8:55 AM EDT

Major Pharma Short Interest Takes a Big Step Back

The July 14 short interest data have been compared with the previous figures, and short interest in most of these…

Lee Jackson | Jul 19, 2017 at 9:42 AM EDT

SunTrust Says Big Pharmaceuticals Have Multiple Catalysts for the Rest of 2017

A new report from SunTrust Robinson Humphrey indicates big pharmaceuticals may be the place to be for investors. Among the…

Chris Lange | Jul 13, 2017 at 9:20 AM EDT

Major Pharma Short Sellers Become More Selective

The June 30 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Jun 27, 2017 at 8:45 AM EDT

Short Sellers Run for Cover From Major Pharma

The June 15 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jun 12, 2017 at 8:55 AM EDT

Short Sellers Grow More Selective on Major Pharma

The May 31 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Jun 2, 2017 at 1:35 PM EDT

15 Companies Bracing for Big ASCO Reactions

24/7 Wall St. takes a look at the ASCO annual meeting each year and picks out the companies that could…

Chris Lange | May 27, 2017 at 8:40 AM EDT

Big Pharma Has Big Catalysts Coming for the Rest of 2017

A new Deutsche Bank research report focuses on the big capitalization pharmaceutical stocks and the upcoming catalysts and news flow…

Chris Lange | May 25, 2017 at 9:45 AM EDT

Major Pharma Short Interest Surges

The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | May 17, 2017 at 12:10 PM EDT

Why This Humira Patent Loss Might Not Be What You Think

AbbVie watched its shares slide on Wednesday following a ruling from the U.S. Patent and Trade Mark Office's Trial and…

Paul Ausick | May 15, 2017 at 11:35 AM EDT

Top Credit Suisse Pharma Picks Ahead of Catalysts

Credit Suisse provided its outlook for several large-cap pharmaceutical stocks Monday morning. The analyst has three top picks to consider.

Chris Lange | May 10, 2017 at 9:00 AM EDT

Short Interest in Major Pharma Shrinks

The April 28 short interest data have been compared with the previous figures, and short interest moves in these selected…

Lee Jackson | Apr 27, 2017 at 8:30 AM EDT

Jefferies Makes a Huge Surprise Addition to Franchise Picks Portfolio

The analysts at Jefferies have made a big move by adding a top consumer goods/auto parts company to the firm's…

Chris Lange | Apr 26, 2017 at 11:30 AM EDT

AbbVie, Celgene and 2 More Major Biotechs Reporting Earnings Thursday

24/7 Wall St. has put together a preview of some of the world’s largest biotech and pharma companies reporting their…

Chris Lange | Apr 26, 2017 at 8:25 AM EDT

Short Sellers Can’t Make Up Their Minds on Major Pharma

The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected…

1 … 22 23 24 25 26 … 38

AbbVie : ABBV

All AbbVie Articles

Major Pharma Short Interest Takes a Big Step Back

SunTrust Says Big Pharmaceuticals Have Multiple Catalysts for the Rest of 2017

Major Pharma Short Sellers Become More Selective

Short Sellers Run for Cover From Major Pharma

Short Sellers Grow More Selective on Major Pharma

15 Companies Bracing for Big ASCO Reactions

Top Presentations to Look for at ASCO

Big Pharma Has Big Catalysts Coming for the Rest of 2017

Major Pharma Short Interest Surges

Why This Humira Patent Loss Might Not Be What You Think

Top Credit Suisse Pharma Picks Ahead of Catalysts

Short Interest in Major Pharma Shrinks

Jefferies Makes a Huge Surprise Addition to Franchise Picks Portfolio

AbbVie, Celgene and 2 More Major Biotechs Reporting Earnings Thursday

Short Sellers Can’t Make Up Their Minds on Major Pharma

Live: Will Palantir Beat Q1 Earnings Tonight After Market Close?

Live: onsemi Q1 Earnings Tonight. Can the Stock Continue Its 90% YTD Rally?

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

AbbVie : ABBV

All AbbVie Articles

Major Pharma Short Interest Takes a Big Step Back

SunTrust Says Big Pharmaceuticals Have Multiple Catalysts for the Rest of 2017

Major Pharma Short Sellers Become More Selective

Short Sellers Run for Cover From Major Pharma

Short Sellers Grow More Selective on Major Pharma

15 Companies Bracing for Big ASCO Reactions

Top Presentations to Look for at ASCO

Big Pharma Has Big Catalysts Coming for the Rest of 2017

Major Pharma Short Interest Surges

Why This Humira Patent Loss Might Not Be What You Think

Top Credit Suisse Pharma Picks Ahead of Catalysts

Short Interest in Major Pharma Shrinks

Jefferies Makes a Huge Surprise Addition to Franchise Picks Portfolio

AbbVie, Celgene and 2 More Major Biotechs Reporting Earnings Thursday

Short Sellers Can’t Make Up Their Minds on Major Pharma

Live: Will Palantir Beat Q1 Earnings Tonight After Market Close?

Live: onsemi Q1 Earnings Tonight. Can the Stock Continue Its 90% YTD Rally?

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how